BACKGROUND: Both angiotensin-converting enzyme inhibitors (ACE-I(s)) and angiotensin receptor blockers (ARB(s)) provide vascular protection. This study was designed to compare ACE-I(s) with widely differing tissue affinity (captopril and quinapril) and an ARB (losartan) on vascular protection against the adverse effects of high cholesterol. METHODS AND RESULTS: Forty-two New Zealand rabbits on a 0.5% cholesterol diet were randomized into control, captopril (10 mg/kg/d), quinapril (0.3 mg/kg/d), and losartan (8 mg/kg/d) groups for 14 weeks. Captopril, quinapril, and losartan significantly attenuated aortic lipid lesions (P=0.001). Captopril and quinapril were more effective than losartan in preserving vascular relaxation. CONCLUSIONS: Captopril, quinapril, and losartan had similar protective effects against atherogenesis. Captopril and quinapril were more effective than losartan in preserving vascular function. Increased bradykinin by ACE inhibition may be responsible for this improved vascular endothelial function.
BACKGROUND: Both angiotensin-converting enzyme inhibitors (ACE-I(s)) and angiotensin receptor blockers (ARB(s)) provide vascular protection. This study was designed to compare ACE-I(s) with widely differing tissue affinity (captopril and quinapril) and an ARB (losartan) on vascular protection against the adverse effects of high cholesterol. METHODS AND RESULTS: Forty-two New Zealand rabbits on a 0.5% cholesterol diet were randomized into control, captopril (10 mg/kg/d), quinapril (0.3 mg/kg/d), and losartan (8 mg/kg/d) groups for 14 weeks. Captopril, quinapril, and losartan significantly attenuated aortic lipid lesions (P=0.001). Captopril and quinapril were more effective than losartan in preserving vascular relaxation. CONCLUSIONS:Captopril, quinapril, and losartan had similar protective effects against atherogenesis. Captopril and quinapril were more effective than losartan in preserving vascular function. Increased bradykinin by ACE inhibition may be responsible for this improved vascular endothelial function.
Authors: Francesco Cacciatore; Giuseppe Bruzzese; Dino Franco Vitale; Antonio Liguori; Filomena de Nigris; Carmela Fiorito; Teresa Infante; Francesco Donatelli; Pellegrino Biagio Minucci; Louis Joseph Ignarro; Claudio Napoli Journal: Eur J Clin Pharmacol Date: 2011-03-29 Impact factor: 2.953
Authors: Daiana Weiss; Kenneth E Bernstein; Sebastian Fuchs; Jonathan Adams; Andreas Synetos; W Robert Taylor Journal: Atherosclerosis Date: 2009-10-06 Impact factor: 5.162
Authors: Eigil Fossum; Michael Hecht Olsen; Aud Høieggen; Kristian Wachtell; Henrik M Reims; Sverre E Kjeldsen; Hans Ibsen; Ying Wan; Stevo Julius Journal: J Clin Hypertens (Greenwich) Date: 2006-03 Impact factor: 3.738